2024

1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

   Lung Cancer, Vol. 194

2. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

   British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424

3. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

   Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789